aggressive lymphoma
radio-immunotherapy
Radio-immunotherapy has no established role in aggressive lymphoma. In patients with relapsed diffuse large B-cell lymphoma (DLBCL) a recent study demonstrated that single agent [ 90 Y]ibritumomab-tiuxetan can induce further remissions. However, while the overall response rate (ORR) was 53% in rituximab-naive patients, it was only 19% in patients pretreated with rituximab [complete remission (CR)/ complete remission unconfirmed (CRu) rate 12%] [2] . These data demonstrate that the efficacy of radio-labeled anti-CD20 antibodies is highly dependent on previous therapy with the naked antibody. Only a head-to-head comparison of a radio-labeled and a naked antibody in a prospective, randomized study will ultimately show whether there is a role for [
90 Y]ibritumomab-tiuxetan or [ 131 I]tositumomab in patients with aggressive lymphoma. Such studies are ongoing. It should be mentioned that new radio-immunoconjugates are being developed and animal experiments have shown promising results [3] .
first-line therapy including rituximab
A number of prospective, randomized, phase III studies have shown that the addition of rituximab to cyclophosphamideadriamycin-vincristine-prednisone (CHOP) significantly improves the outcome of patients with DLBCL. The first study was reported by Coiffier et al. [4] and was updated recently [5] . The French study group Groupe d'Etude des Lymphomes de l'Adulte (GELA) treated 399 patients aged 60-80 years with eight courses of CHOP-21 or R-CHOP-21 (time interval between treatment courses was 21 days). The 7-year progression-free survival (PFS) was 52% for R-CHOP and 29% for CHOP (P < 0.0001), overall survival (OS) was 53% for R-CHOP versus 36% for CHOP (P = 0.0004). Benefit was observed in patients with low-risk and high-risk International Prognostic Index (IPI).
The recently published RICOVER-60 study by the German High-grade Lymphoma Study Group (DSHNHL) treated elderly patients with aggressive B-cell lymphomas, mostly DLBCL, using either six or eight courses of CHOP-14 or R-CHOP-14 (time interval between treatment courses 14 days). The best results were obtained with six courses of R-CHOP-14. The 3-year event-free survival (EFS) rate and OS rate were 67% and 78%, respectively, and proved significantly better than the EFS and OS observed after six courses of CHOP-14 or eight courses of CHOP-14 or R-CHOP-14 [6] .
Other studies like the US Intergroup/Eastern Cooperative Oncology Group (ECOG) trial [7] or the HOVON trial [8] also showed that the addition of rituximab to CHOP-21 or CHOP-14 significantly improves the outcome for elderly patients (>60 years) with aggressive B-cell lymphomas.
In younger patients with good-risk DLBCL the MInT (Mabthera International Trial) study demonstrated that the addition of rituximab to six courses of CHOP or CHOP-like chemotherapy significantly improved EFS and OS. At a median symposium article follow-up of 34 months patients treated with CHOP-like therapy and rituximab had a 3-year EFS of 79% compared with 59% in patients treated with chemotherapy alone (P < 0.0001). OS was increased from 84% to 93% in patients given rituximab (P = 0.0001). This study for the first time in the history of lymphoma therapy showed a 100% 3-year OS in the favorable subgroup of patients (IPI 0, no bulky disease) treated with R-CHOP-21 [9] . There is no study to date formally demonstrating an advantage of the addition of rituximab to chemotherapy in young, high-risk patients [age-adjusted IPI (aaIPI) 2 and 3] with DLBCL. This is largely due to the fact that most study groups use high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) in these patients. The addition of rituximab to HDT/ASCT is feasible and safe with high rates of CR and good EFS and OS [10] .
relapsed disease and rituximab
Single-agent activity of rituximab in patients with relapsed DLBCL was first shown by Coiffier in 1998 [11] . A number of phase II studies have demonstrated that rituximab could safely be combined with salvage chemotherapy like the iphosphamide-carboplatin-etoposide (ICE) or cisplatincytarabine-dexamethasone (DHAP) regimen [12, 13] .
Currently, a randomized phase III study comparing R-DHAP with R-ICE followed by carmustine-cytarabine-etoposidemelphalan (BEAM) HDT and ASCT is about to be closed [14] . This study is important because for the first time two salvage regimens have been compared head-to-head; additionally, patients are randomized to rituximab maintenance or observation following HDT/ASCT. Thus, the role of maintenance therapy in patients with relapsed DLBCL who achieve a remission after HDT/ASCT will be clarified.
follicular lymphoma first-line therapy including rituximab
The addition of rituximab to the previously known therapeutic options may for the first time alter the clinical course of patients with follicular lymphoma (FL) and some patients hopefully will be cured or at least enjoy long-lasting remission. In contrast to the situation in aggressive lymphoma, the situation in FL is much more complex because rituximab may be used as single agent or together with mono-or combination chemotherapy. Furthermore, maintenance therapy with rituximab after any of these treatments may further improve treatment outcome.
Several groups investigated the use of rituximab as front-line therapy for FL [15] [16] [17] [18] [19] . The ORR was in the order of 75% with almost half of these patients achieving CR. Most patients, however, progressed between 1 and 2 years after initial therapy and needed re-treatment. In order to prevent or postpone relapse several strategies have been proposed. At this time, it is not yet clear whether prolonged treatment with rituximab as proposed by the Swiss SAKK group [18] or re-treatment at the time of relapse [16] will ultimately yield the best results. Randomized phase III studies comparing these strategies are ongoing.
At least four randomized studies have addresses the question of whether the addition of rituximab to various chemotherapy protocols improves PFS and/or OS. These studies all demonstrated a significant improvement of PFS and OS when rituximab was added to chemotherapy. However, different chemotherapies were used, and consolidation/maintenance therapy included a variety of modalities [interferon (IFN) combined with cyclophosphamide-doxorubicin-vindesineprednisone (CHVP), consolidation with HDT/ASCT, rituximab maintenance] (Table 1) . Therefore, it is not possible to delineate the best approach in patients with FL from these trials. A risk-adapted procedure may be most adequate.
relapsed disease and rituximab
The addition of rituximab to salvage chemotherapy improves the response rates and prolongs OS in relapsed and refractory follicular and mantle cell lymphoma. Chemotherapy may consist of standard CHOP in patients not previously treated with an anthracycline-containing regimen [25] or the more aggressive fludarabine-cyclophosphamide-mitoxantrone (FCM) regimen [26] in patients pretreated with CHOP. The ORR was increased by 15-20% in both studies if rituximab was added. Maintenance therapy with rituximab further improved the results. In the EORTC study reported by van Oers et al. [25] , OS from second randomization was 85% with rituximab and 77% without rituximab at 3 years. The German Low Grade Lymphoma Study Group showed that OS at 3 years was 77% in patients with maintenance therapy and 57% after observation only [27] .
the role of radio-immunotherapy 131 I]tositumomab is superior to re-treatment with rituximab chemotherapy in patients with relapsed/refractory FL who have been exposed to rituximab as part of first-line therapy. Unfortunately, no phase III data are available to answer this question.
Radio-immunotherapy has been used as single agent and as part of multi-agent therapy in first-line treatment of FL (Table 2) .
Kaminski et al. [31] [32] , CVP [33] or R-CHOP [29, 30] , as first-line therapy for indolent NHL. All of these studies have shown excellent response rates with ORR ranging from 90% to 100% and CR rates of 60-90%. The treatments were well tolerated with no unpredicted toxicities and many patients achieved durable remissions of >5 years.
As in relapsed or refractory disease, there is no published study addressing the question of whether either [ 90 Y]ibritumomab-tiuxetan or [ 131 I]tositumomab given in conjunction with poly-chemotherapy results in better response and response duration than the combination of rituximab and the identical chemotherapy regimen as first-line therapy of FL. Given the fact that radio-immunotherapy is more cumbersome to administer and several other restrictions apply (e.g. no bone marrow involvement >25%) only such a study will convince the majority of oncologists to prefer radio-immunotherapy over immunotherapy with the naked antibody.
aggressive T-cell lymphoma
The humanized anti-CD52 immunoglobulin G1 monoclonal antibody alemtuzumab (MabCampath) is increasingly being used to treat aggressive T-cell lymphoma. The single-agent activity has been modest (ORR 36% in a pilot study published by Enblad et al. [35] ). Toxicity was severe and included cytomegalovirus (CMV) reactivation, pulmonary aspergillosis, pancytopenia and Epstein-Barr virus (EBV)-related hemophagocytosis. Currently, the combination of alemtuzumab with the CHOP regimen is under investigation [36] . A prospective, randomized, phase III study conducted by the DSHNHL and the Nordic Lymphoma Group compares CHOP with A-CHOP.
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